MHC Class I Antigens and Immune Surveillance in Transformed Cells
The DOI matches its Crossref record; 252 of the 256 references it cites were found in a registry or an index.
Abstract
MHC class I antigens play a crucial role in the interaction of tumor cells with the host immune system, in particular, in the presentation of peptides as tumor-associated antigens to cytotoxic lymphocytes (CTLs) and in the regulation of cytolytic activity of natural killer (NK) cells. In this review we discuss the role of MHC class I antigens in the recognition and elimination of transformed cells and in the generation of tumor immune escape routes when MHC class I losses occur in tumors. The different altered MHC class I phenotypes and their distribution in different human tumors are the main topic of this review. In addition, molecular defects that underlie MHC alterations in transformed cells are also described in detail. Future research directions in this field are also discussed, including the laboratory analysis of tumor MHC class I-negative variants and the possible restoration of MHC class I expression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous work has reported loss of heterozygosity (LOH) of HLA-I genes in cancer (43, 44).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [43]
Citations
Cites
Items 201–252 of 252
Kulig, K., Nandi, D., Bačík, I., Monaco, J. J., & Vukmanović, S. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.6.865 · Cited by 44
Miyagi, T., Tatsumi, T., Takehara, T., Kanto, T., Kuzushita, N., Sugimoto, Y., Jinushi, M., Kasahara, A., Sasaki, Y., Hori, M., et al. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.02921.x · Cited by 42
Howcroft, T. K., Raval, A., Weissman, J. D., Gegonne, A., & Singer, D. S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.10.3377-3391.2003 · Cited by 40
Criteria to define HLA haplotype loss in human solid tumors
Ramal, L. M., Feenstra, M., Zwan, A. ‐. V. D., Collado, A., López‐Nevot, M. Á., Tilanus, M. G. J., & Garrido, F. (2000) · Tissue Antigens · doi:10.1034/j.1399-0039.2000.550507.x · Cited by 40
Self-citationPérez, M., Algarra, I., Ljunggren, H., Caballero, A., Mialdea, M. J., Gaforio, J. J., Klein, G. O., Kärre, K., & Garrido, F. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910460219 · Cited by 39
Self-citationPhenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas.
López‐Nevot, M. Á., García, E., Romero, C., Mr, O., Serrano, S., & Garrido, F. (1988) · PubMed · Cited by 39
Self-citationThe great escape: Is immune evasion required for tumor progression?
Villunger, A., & Strasser, A. (1999) · Nature Medicine · doi:10.1038/11311 · Cited by 38
Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29.
Wang, Z., Seliger, B., Mike, N., Momburg, F., Knuth, A. K., & Ferrone, S. (1998) · PubMed · Cited by 38
Peltenburg, L. T. C., & Schrier, P. I. (1994) · Immunogenetics · doi:10.1007/bf00163964 · Cited by 37
Priming in the brain, an immunologically privileged organ, elicits anti-tumor immunity
Fathallah‐Shaykh, H. M., Gao, W., Cho, M., & Herrera, M. A. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980119)75:2<217::aid-ijc9>3.0.co;2-x · Cited by 36
Self-citationHLA class I expression in bladder carcinomas
Cabrera, T., Pedrajas, G., Cozar, J. M., Garrido, A., Vicente, J., Tallada, M., & Garrido, F. (2003) · Tissue Antigens · doi:10.1034/j.1399-0039.2003.00104.x · Cited by 36
Self-citationRodríguez, T., M�ndez, R., Roberts, C. H., Ruiz‐Cabello, F., Dodi, I. A., López‐Nevot, M. Á., Paco, L., Maleno, I., Marsh, S. G. E., Pawelec, G., et al. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0561-5 · Cited by 36
Self-citationReal, L. M., Jimenez, P., Cantón, J., Kirkin, A. F., Garcia-Lora, A. M., Abril, E., Zeuthen, J., Ruiz‐Cabello, F., & Garrido, F. (1998) · International Journal of Cancer · Cited by 36
Self-citationMéndez, R., Serrano, A., Jäger, E., Maleno, I., Ruiz‐Cabello, F., Knuth, A. K., & Garrido, F. (2001) · Tissue Antigens · doi:10.1034/j.1399-0039.2001.057006508.x · Cited by 35
Self-citationMaleno, I., López‐Nevot, M. Á., Seliger, B., & Garrido, F. (2004) · International Journal of Cancer · doi:10.1002/ijc.20000 · Cited by 34
Self-citationMutation in the β2m gene is not a frequent event in head and neck squamous cell carcinomas
Feenstra, M., Rozemuller, E. H., Duran, K. J., Stuij, I., van den Tweel, J. G., Slootweg, P. J., de Weger, R. A., & Tilanus, M. G. J. (1999) · Human Immunology · doi:10.1016/s0198-8859(99)00015-4 · Cited by 33
Involvement of the chaperone tapasin in HLA-B44 allelic losses in colorectal tumors
Cabrera, C. M., López‐Nevot, M. Á., Jiménez, P., & Garrido, F. (2004) · International Journal of Cancer · doi:10.1002/ijc.20526 · Cited by 32
Self-citationLoss of heterozygosity in the HLA class I region in human pancreatic cancer
Ryschich, E., Cebotari, O., Fabian, O. V., Autschbach, F., Kleeff, J. H., Frieß, H., Bierhaus, A., Büchler, M. W., & Schmidt, J. (2004) · Tissue Antigens · doi:10.1111/j.1399-0039.2004.00324.x · Cited by 31
Bergen, M., Chen, R. E., & Gonzalez, R. C. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.2.377 · Cited by 30
Serrano, A., Brady, C. S., Jimenez, P., Duggan-Keen, M. F., Méndez, R., Stern, P. L., Garrido, F., & Ruiz‐Cabello, F. (2000) · Immunogenetics · doi:10.1007/s002510000239 · Cited by 30
Self-citationAlgarra, I., Gaforio, J. J., Garrido, A., Mialdea, M. J., Pérez, M., & Garrido, F. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910470716 · Cited by 30
Self-citationGarrido, A., Pérez, M., Delgado, C. H., Ml, G., Rojano, J., Algarra, I., & Garrido, F. (1986) · PubMed · Cited by 30
Self-citationImmunology Signal sequences stop killer cells
Long, E. O. (1998) · Nature · doi:10.1038/35739 · Cited by 29
Loss of Human Leukocyte Antigen Expression on Colorectal Tumor Cell Lines
Browning, M. J., Krausa, P., Rowan, A., Hill, A. B., Bicknell, D. C., Bodmer, J. G., & Bodmer, W. F. (1993) · Journal of Immunotherapy · doi:10.1097/00002371-199310000-00001 · Cited by 29
High frequency of HLA-B44 allelic losses in human solid tumors
Cabrera, T., Maleno, I., López‐Nevot, M. Á., Redondo, M., Fernandez, M. A., Collado, A., & Garrido, F. (2003) · Human Immunology · doi:10.1016/s0198-8859(03)00164-2 · Cited by 29
Self-citationSnell, G. D. (1952) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/13.3.719 · Cited by 28
Feenstra, M., Verdaasdonk, M. A. M., Zwan, A. ‐. V. D., de Weger, R. A., Slootweg, P. J., & Tilanus, M. G. J. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780045 · Cited by 28
Drénou, B., Tilanus, M. G. J., Sémana, G., Alizadeh, M., Birebent, B., Grosset, J., Dias, P. C., van Wichen, D. F., Arts, Y., Santis, D. D., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05151.x · Cited by 28
Jiménez, P., Cabrera, T., Méndez, R., Esparza, C., Cozar, J. M., Tallada, M., López‐Nevot, M. Á., Ruiz‐Cabello, F., & Garrido, F. (2001) · Immunogenetics · doi:10.1007/s002510100371 · Cited by 27
Self-citationMHC loss in colorectal tumours: evidence for immunoselection?
Kaklamanis, L., & Hill, A. (1992) · PubMed · Cited by 26
Tafuro, S., Meier, U., Dunbar, P. R., Jones, E. Y., Layton, G. T., Hunter, M. G., Bell, J. I., & McMichael, A. J. (2001) · European Journal of Immunology · Cited by 26
MHC CLASS I AND II ANTIGENS ON GASTRIC CARCINOMAS AND AUTOLOGOUS MUCOSA
FERRON, A. D., Perez‐Ayala, M., Concha, Á., Cabrera, T., Redondo, M., Oliva, M. R., Ruiz‐Cabello, F., & Garrido, F. (1989) · International Journal of Immunogenetics · doi:10.1111/j.1744-313x.1989.tb00489.x · Cited by 25
Self-citationLiu, K., & Abrams, S. I. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.5973 · Cited by 23
Selection of metastatic tumour phenotypes by host immune systems
Seymour, K., Pettit, S. J., O'Flaherty, E., Charnley, R., & Kirby, J. A. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04435-9 · Cited by 19
Koene, G. J. P. A., Hilkes, Y. H. A., van der Ven, K. J. W., Rozemuller, E. H., Slootweg, P. J., de Weger, R. A., & Tilanus, M. G. J. (2004) · Tissue Antigens · doi:10.1111/j.1399-0039.2004.00291.x · Cited by 19
Mechanisms of Tumor Escape from the Immune Response
(2002) · CRC Press eBooks · doi:10.1201/9781482265149 · Cited by 19
HLA Class I and II Expression in Rhabdomyosarcomas
Fernández, J. E., Concha, Á., Aránega, A., Ruiz‐Cabello, F., Cabrera, T., & Garrido, F. (1991) · Immunobiology · doi:10.1016/s0171-2985(11)80208-1 · Cited by 18
Self-citationAntigen Processing, Where Tumor-Specific T-Cell Responses Begin
Bennink, J. R., Anderson, R., Bačík, I., Cox, J. H., Day, P. M., Deng, Y., Lapham, C. K., Link, H. T., Russ, G., & Yewdell, J. W. (1993) · Journal of Immunotherapy · doi:10.1097/00002371-199310000-00006 · Cited by 18
β2-microglobulin gene mutation is not a common mechanism of HLA class I total loss in human tumors
Fernández, M. A., Ruiz‐Cabello, F., Oliva, M. R., Cabrera, T., Jiménez, P., López‐Nevot, M. Á., & Garrido, F. (2000) · International Journal of Clinical & Laboratory Research · doi:10.1007/bf02874164 · Cited by 17
Self-citationMechanisms of Tumor Escape from the Immune Response
Ochoa, A. (2002) · doi:10.1201/9780367804701 · Cited by 15
Development of cancer vaccines to activate cytotoxic T lymphocytes
Durrant, L., & Ramage, J. M. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.4.555 · Cited by 14
Reduced expression of MHC class I antigen in human cancer cell lines with defective LMP-7.
Yoon, S. J., Kang, J.-O., Park, J. S., Kim, N. K., & Heo, D. S. (2000) · PubMed · Cited by 12
Regulation of Tumor Progression by Anti-Neoplastic T Cell Responses
Abrams, S. I. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.2.758 · Cited by 9
Biologic effects of the altered MHS profile on the K36 tumor, a spontaneous leukemia of AKR.
Festenstein, H., Schmidt, W., Testorelli, C., Marelli, O., & Simpson, S. (1980) · PubMed · Cited by 7
Kovalcsik, E., John, J., Turner, M., Birchall, L., Sage, D. A., Whittle, R., Dalgleish, A. G., & Pandha, H. (2004) · Melanoma Research · doi:10.1097/00008390-200412000-00005 · Cited by 7
Hara, M., Matsueda, S., Tamura, M., Takedatsu, H., Tanaka, M., Kawano, K., Mochizuki, K., Kamura, T., Itoh, K., & Harada, M. (2005) · International Journal of Oncology · doi:10.3892/ijo.27.5.1371 · Cited by 6
Invasion and metastasis control: implications for increased therapeutic index of antitumor drugs
Mareel, M., Bracke, M., Bruyneel, E. A., Larebeke, N. V., & Mets, M. D. (1990) · Cancer Treatment Reviews · doi:10.1016/0305-7372(90)90066-o · Cited by 5
Universities Vie for DOD Software Center
Walsh, J. C. (1984) · Science · doi:10.1126/science.226.4670.26 · Cited by 5
Bergen, M., Chen, R. E., & Gonzalez, R. C. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/eobt.3.2.377.21150 · Cited by 4
Tsory, S., Kellman-Pressman, S., Fishman, D., & Segal, S. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.08.008 · Cited by 3
Lack of sufficient B7 expression as a tumor escape mechanism: implications for immunotherapy
Schultze, J. L., & Nadler, L. M. (2002) · CRC Press eBooks · doi:10.1201/9781482265149-4 · Cited by 3
Activation of MAPK and AKT pathways by BRAF, NRAS and PIK3CA mutations in melanoma
Libra, M., Malaponte, G., Ligresti, G., Gangemi, P., Siciliano, R., Travali, S., Mazzarino, M. C., Mangano, K., Nicoletti, F., Wong, E. W. T., et al. (2007) · Cancer Research · Cited by 1
Research works printed but not linked: 1
- Snell, 1952, Enhancement and inhibition of the growth of tumor homotransplants by pre‐treatment of the hosts with various preparations of normal and tumor tissue, J. Natl. Cancer Inst., 13, 719
Cited by
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817
The HLA genomic loci map: expression, interaction, diversity and disease
Shiina, T., Hosomichi, K., Inoko, H., & Kulski, J. K. (2009) · Journal of Human Genetics · doi:10.1038/jhg.2008.5 · Cited by 782
Fu, Y., Sun, Y., Li, Y., Li, J., Rao, X., Chen, C., & Xu, A. (2011) · Genome Research · doi:10.1101/gr.115295.110 · Cited by 270
“This down-regulation could help the cancer cell to escape elimination by cytotoxic T cells, though complete loss of HLA class I molecules could also induce NK cell lysis (See reviews in Aptsiauri et al. [2007a]; Aptsiauri et al.”
Background
Metadata
- Authors
- Aptsiauri, N., Cabrera, T., Garcia‐Lora, A., Lopez‐Nevot, M. A., Ruiz‐Cabello, F., & Garrido, F.
- Affiliations
- Hospital Universitario Virgen de las Nieves (ES)
- Universidad de Granada (ES)
- Venue
- International Review of Cytology
- Publisher
- Elsevier
- Published
- 2007
- Volume
- 256
- Pages
- 139-189
- ISSN
- 0074-7696 (ISSN-L)
- OpenAlex
- W1493511814
- Cited by
- 145
- References
- 256
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 11 · 2020: 7 · 2019: 10 · 2018: 7 · 2017: 10 · 2016: 8 · 2015: 6 · 2014: 9 · 2013: 11 · 2012: 7
- FWCI
- 16.01
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- International review of cytology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- MHC class I antigens, tumor immune evasion, MHC class I loss, tumor-associated antigens, cytotoxic T lymphocytes, natural killer cells, immune surveillance, transformed cells, tumor immunology
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Immunologic Surveillance, Killer Cells, Natural, Models, Biological, Neoplasms, T-Lymphocytes, Histocompatibility Antigens Class I, Antigen Presentation, Disease Progression, Tumor Escape
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.